Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2021-12-03 Purchase |
2021-12-06 8:34 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
30,000 | $14.43 | $432,876 | 571,376 (Indirect Direct) |
View |
2021-08-16 Sale |
2021-08-17 6:20 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
9,364 | $26.34 | $246,659 | 541,376 (Indirect Direct) |
View |
2021-07-28 Sale |
2021-07-30 8:57 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
54,332 | $30.06 | $1,632,960 | 234,078 (Indirect Direct) |
View |
2021-07-26 Sale |
2021-07-28 9:48 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
55,382 | $29.72 | $1,645,953 | 610,021 (Indirect Direct) |
View |
2021-04-05 Sale |
2021-04-06 7:41 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
2 | $28.28 | $57 | 665,403 (Indirect Direct) |
View |
2021-03-04 Sale |
2021-03-05 8:10 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $25.43 | $842,216 | 665,405 (Indirect Direct) |
View |
2021-02-01 Sale |
2021-02-03 8:13 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $25.95 | $859,438 | 686,619 (Indirect Direct) |
View |
2020-12-30 Sale |
2021-01-04 8:01 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $27.82 | $921,212 | 719,738 (Indirect Direct) |
View |
2020-11-30 Sale |
2020-12-02 8:55 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $23.85 | $789,888 | 752,857 (Indirect Direct) |
View |
2020-10-29 Sale |
2020-10-30 8:24 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $26.15 | $865,949 | 785,976 (Indirect Direct) |
View |
2020-09-28 Sale |
2020-09-30 9:21 pm |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,119 | $26.18 | $867,055 | 819,095 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2022-03-15 Tax Withholding |
2022-03-17 5:50 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey Director |
1,372 | $15.79 | 570,004 (Direct) |
View |
2021-08-15 Tax Withholding |
2021-08-17 6:20 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
4,949 | $26.02 | 541,376 (Direct) |
View |
2021-02-02 Option Award |
2021-02-04 9:16 pm |
N/A 2031-02-01 |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
33,445 | $0 | 720,064 (Direct) |
View |
2020-07-23 Option Award(A) |
2020-09-30 9:19 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
667,292 | $0 | 677,912 (Direct) |
View |
2020-07-23 Option Award |
2020-07-27 7:57 pm |
N/A 2029-05-13 |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
53,695 | $2.54 | 982,440 (Direct) |
View |
2020-07-23 Option Award |
2020-07-27 7:57 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
667,292 | $0 | 982,440 (Direct) |
View |
Ownership |
2020-07-27 7:55 pm |
N/A N/A |
Revance Therapeutics Inc. | RVNC | Rankin Aubrey President, Innovation & Tech |
0 | $0 | 272,073 (Direct) |
View |